SE0202241D0 - Novel Compounds - Google Patents
Novel CompoundsInfo
- Publication number
- SE0202241D0 SE0202241D0 SE0202241A SE0202241A SE0202241D0 SE 0202241 D0 SE0202241 D0 SE 0202241D0 SE 0202241 A SE0202241 A SE 0202241A SE 0202241 A SE0202241 A SE 0202241A SE 0202241 D0 SE0202241 D0 SE 0202241D0
- Authority
- SE
- Sweden
- Prior art keywords
- novel compounds
- relates
- present
- pharmaceutical compounds
- respiratory disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Transplantation (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
Priority Applications (27)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0202241A SE0202241D0 (sv) | 2002-07-17 | 2002-07-17 | Novel Compounds |
SE0203713A SE0203713D0 (sv) | 2002-07-17 | 2002-12-13 | Novel compounds |
TW092118486A TW200404778A (en) | 2002-07-17 | 2003-07-07 | Novel compounds |
PCT/SE2003/001216 WO2004007451A1 (en) | 2002-07-17 | 2003-07-15 | Indole-3-sulphur derivatives |
BR0312729-0A BR0312729A (pt) | 2002-07-17 | 2003-07-15 | Novos derivados de indol-3-enxofre |
US10/521,325 US7723373B2 (en) | 2002-07-17 | 2003-07-15 | Indole-3-sulphur derivatives |
JP2004521364A JP4791729B2 (ja) | 2002-07-17 | 2003-07-15 | インドール−3−硫黄誘導体 |
SI200331737T SI1551802T1 (sl) | 2002-07-17 | 2003-07-15 | Indol žveplovi derivati |
CA002492445A CA2492445A1 (en) | 2002-07-17 | 2003-07-15 | Indole-3-sulphur derivatives |
AT03764279T ATE450506T1 (de) | 2002-07-17 | 2003-07-15 | Indol-3-schwefelderivate |
CNB038199718A CN1279023C (zh) | 2002-07-17 | 2003-07-15 | 吲哚-3-硫衍生物 |
EP03764279A EP1551802B1 (en) | 2002-07-17 | 2003-07-15 | Indole-3-sulphur derivatives |
PT03764279T PT1551802E (pt) | 2002-07-17 | 2003-07-15 | Derivados de indole-3-enxofre |
DK03764279.0T DK1551802T3 (da) | 2002-07-17 | 2003-07-15 | Indol-3-svovlderivater |
NZ537606A NZ537606A (en) | 2002-07-17 | 2003-07-15 | Indole-2-sulphur derivatives and their use to treat prostaglandin D2 mediated diseases |
MXPA05000646A MXPA05000646A (es) | 2002-07-17 | 2003-07-15 | Derivados de indol-3-azufre. |
DE60330372T DE60330372D1 (de) | 2002-07-17 | 2003-07-15 | Indol-3-schwefelderivate |
ES03764279T ES2335491T3 (es) | 2002-07-17 | 2003-07-15 | Derivados de indol-3-azufre. |
AU2003251260A AU2003251260B2 (en) | 2002-07-17 | 2003-07-15 | Indole-3-sulphur derivatives |
AR20030102585A AR040498A1 (es) | 2002-07-17 | 2003-07-17 | Indoles sustituidos utiles para el tratamiento de enfermedades respiratorias |
IL16612105A IL166121A0 (en) | 2002-07-17 | 2005-01-03 | Indole-3-sulphur derivatives |
ZA200500170A ZA200500170B (en) | 2002-07-17 | 2005-01-07 | Indole-3-sulphur derivatives. |
NO20050828A NO20050828L (no) | 2002-07-17 | 2005-02-16 | lndol-3-svovelderivater |
CY20101100086T CY1109760T1 (el) | 2002-07-17 | 2010-01-28 | Παραγωγα ινδολης-3-θειου |
US12/758,348 US20100197756A1 (en) | 2002-07-17 | 2010-04-12 | Indole-3-Sulphur Derivatives |
JP2010166138A JP2010280680A (ja) | 2002-07-17 | 2010-07-23 | インドール−3−硫黄誘導体 |
JP2011043693A JP2011116770A (ja) | 2002-07-17 | 2011-03-01 | インドール−3−硫黄誘導体 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0202241A SE0202241D0 (sv) | 2002-07-17 | 2002-07-17 | Novel Compounds |
SE0203713A SE0203713D0 (sv) | 2002-07-17 | 2002-12-13 | Novel compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
SE0202241D0 true SE0202241D0 (sv) | 2002-07-17 |
Family
ID=30117585
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE0202241A SE0202241D0 (sv) | 2002-07-17 | 2002-07-17 | Novel Compounds |
SE0203713A SE0203713D0 (sv) | 2002-07-17 | 2002-12-13 | Novel compounds |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE0203713A SE0203713D0 (sv) | 2002-07-17 | 2002-12-13 | Novel compounds |
Country Status (23)
Country | Link |
---|---|
US (2) | US7723373B2 (xx) |
EP (1) | EP1551802B1 (xx) |
JP (3) | JP4791729B2 (xx) |
CN (1) | CN1279023C (xx) |
AR (1) | AR040498A1 (xx) |
AT (1) | ATE450506T1 (xx) |
AU (1) | AU2003251260B2 (xx) |
BR (1) | BR0312729A (xx) |
CA (1) | CA2492445A1 (xx) |
CY (1) | CY1109760T1 (xx) |
DE (1) | DE60330372D1 (xx) |
DK (1) | DK1551802T3 (xx) |
ES (1) | ES2335491T3 (xx) |
IL (1) | IL166121A0 (xx) |
MX (1) | MXPA05000646A (xx) |
NO (1) | NO20050828L (xx) |
NZ (1) | NZ537606A (xx) |
PT (1) | PT1551802E (xx) |
SE (2) | SE0202241D0 (xx) |
SI (1) | SI1551802T1 (xx) |
TW (1) | TW200404778A (xx) |
WO (1) | WO2004007451A1 (xx) |
ZA (1) | ZA200500170B (xx) |
Families Citing this family (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0201635D0 (sv) | 2002-05-30 | 2002-05-30 | Astrazeneca Ab | Novel compounds |
TW200307542A (en) * | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
SE0202241D0 (sv) * | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
SE0301010D0 (sv) | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
SE0301569D0 (sv) * | 2003-05-27 | 2003-05-27 | Astrazeneca Ab | Novel compounds |
RU2356889C2 (ru) | 2003-07-17 | 2009-05-27 | Плекссикон, Инк. | Соединения, являющиеся активными по отношению к рецепторам, активируемым пролифератором пероксисом |
US7348338B2 (en) | 2003-07-17 | 2008-03-25 | Plexxikon, Inc. | PPAR active compounds |
SE0302232D0 (sv) * | 2003-08-18 | 2003-08-18 | Astrazeneca Ab | Novel Compounds |
SA04250253B1 (ar) | 2003-08-21 | 2009-11-10 | استرازينيكا ايه بي | احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن |
CA2542716A1 (en) * | 2003-10-14 | 2005-05-06 | Oxagen Limited | Compounds having crth2 antagonist activity |
SE0303180D0 (sv) * | 2003-11-26 | 2003-11-26 | Astrazeneca Ab | Novel compounds |
SI1725553T1 (sl) | 2004-03-11 | 2008-08-31 | Actelion Pharmaceuticals Ltd | Derivati tetrahidropiridoindola |
GB0412914D0 (en) * | 2004-06-10 | 2004-07-14 | Oxagen Ltd | Compounds |
MY144903A (en) * | 2004-06-17 | 2011-11-30 | Novartis Ag | Pyrrolopyridine derivatives and their use as crth2 antagonists |
GB0415320D0 (en) | 2004-07-08 | 2004-08-11 | Astrazeneca Ab | Novel compounds |
GB0418830D0 (en) | 2004-08-24 | 2004-09-22 | Astrazeneca Ab | Novel compounds |
CN101052397B (zh) * | 2004-08-26 | 2011-07-06 | 埃科特莱茵药品有限公司 | 2-硫烷基-苯并咪唑-1-基-乙酸衍生物 |
EP1805171A4 (en) | 2004-09-21 | 2009-05-13 | Wyeth Corp | CRTH2 RECEPTOR ANTAGONISM DISPLAYING INDIGENOUS ACIDS AND APPLICATIONS THEREOF |
CA2585334C (en) * | 2004-10-27 | 2014-05-13 | Janssen Pharmaceutica N.V. | Indole derivatives useful as progesterone receptor modulators |
UY29223A1 (es) | 2004-11-23 | 2006-06-30 | Astrazeneca Ab | Ácidos fenoxiacéticos sustituidos, composiciones farmacéuticas que los contienen y procesos para su preparación |
JP2008521829A (ja) * | 2004-11-30 | 2008-06-26 | プレキシコン,インコーポレーテッド | Ppar活性化合物 |
WO2006060535A2 (en) * | 2004-11-30 | 2006-06-08 | Plexxikon, Inc. | Indole derivatives for use as ppar active compounds |
PL1833791T3 (pl) | 2004-12-27 | 2011-12-30 | Actelion Pharmaceuticals Ltd | Pochodne 2,3,4,9-tetrahydro-1H-karbazolu jako antagonisty receptora CRTH2 |
GB0500604D0 (en) * | 2005-01-13 | 2005-02-16 | Astrazeneca Ab | Novel process |
JP5024039B2 (ja) * | 2005-02-25 | 2012-09-12 | 小野薬品工業株式会社 | インドール化合物およびその用途 |
GB0505048D0 (en) | 2005-03-11 | 2005-04-20 | Oxagen Ltd | Compounds with PGD antagonist activity |
ES2372701T3 (es) | 2005-07-22 | 2012-01-25 | Shionogi & Co., Ltd. | Derivado de indol que tiene actividad antagonista del receptor de pgd2. |
US7842692B2 (en) | 2005-07-22 | 2010-11-30 | Shionogi & Co., Ltd. | Azaindole derivative having PGD2 receptor antagonistic activity |
US20070027105A1 (en) | 2005-07-26 | 2007-02-01 | Alza Corporation | Peroxide removal from drug delivery vehicle |
EP1931658A2 (en) * | 2005-09-07 | 2008-06-18 | Plexxikon, Inc. | 1 , 4 and 1 , 5-disubstituted indole derivatives for use as ppar active compounds |
BRPI0615948A2 (pt) * | 2005-09-07 | 2011-05-31 | Plexxikon Inc | composto ativo de ppar, sua composição, seu kit e seu uso |
EP1937632A1 (en) | 2005-10-06 | 2008-07-02 | Astra Zeneca AB | Novel compounds |
TW200745003A (en) | 2005-10-06 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
GB0525143D0 (en) | 2005-12-09 | 2006-01-18 | Novartis Ag | Organic compounds |
GB0526257D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
JP2009538289A (ja) * | 2006-05-26 | 2009-11-05 | アストラゼネカ・アクチエボラーグ | ビアリールまたはヘテロアリール置換インドール |
WO2007149312A2 (en) | 2006-06-16 | 2007-12-27 | The Trustees Of The University Of Pennsylvania | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and bph |
JP5270542B2 (ja) | 2006-07-22 | 2013-08-21 | オキサジェン リミテッド | Crth2アンタゴニスト活性を有する化合物 |
KR101411820B1 (ko) | 2006-08-07 | 2014-06-24 | 액테리온 파마슈티칼 리미티드 | (3-아미노-1,2,3,4-테트라하이드로-9h-카르바졸-9-일)-아세트산 유도체 |
PE20090159A1 (es) | 2007-03-08 | 2009-02-21 | Plexxikon Inc | COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs |
UA100983C2 (xx) | 2007-07-05 | 2013-02-25 | Астразенека Аб | Біфенілоксипропанова кислота як модулятор crth2 і інтермедіати$бифенилоксипропановая кислота как модулятор crth2 и интермедиаты |
GB0722055D0 (en) * | 2007-11-09 | 2007-12-19 | Argenta Discovery Ltd | Compounds |
NZ585888A (en) | 2007-12-14 | 2012-02-24 | Pulmagen Therapeutics Asthma Ltd | Indoles and their therapeutic use |
US7750027B2 (en) * | 2008-01-18 | 2010-07-06 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
KR101644170B1 (ko) | 2008-01-18 | 2016-08-01 | 옥사겐 리미티드 | 씨알티에이치2 길항제 활성을 갖는 화합물 |
EP2240444A1 (en) | 2008-01-22 | 2010-10-20 | Oxagen Limited | Compounds having crth2 antagonist activity |
US20100022613A1 (en) | 2008-01-22 | 2010-01-28 | Oxagen Limited | Compounds Having CRTH2 Antagonist Activity |
TWI469965B (zh) | 2008-12-22 | 2015-01-21 | Ono Pharmaceutical Co | 乙炔基吲哚化合物 |
BR112012000353B1 (pt) | 2009-07-06 | 2020-06-02 | Astrazeneca Ab | Composto de fórmula markush, uso do composto, processos de reação com agente de acetilação e processo para preparação de um composto |
WO2011055270A1 (en) | 2009-11-04 | 2011-05-12 | Wyeth Llc | Indole based receptor crth2 antagonists |
BR112012017756A2 (pt) | 2009-12-23 | 2016-04-19 | Ironwood Pharmaceuticals Inc | moduladores crth2 |
WO2011115804A1 (en) | 2010-03-17 | 2011-09-22 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
MY183111A (en) | 2010-03-22 | 2021-02-15 | Idorsia Pharmaceuticals Ltd | 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators |
CA2803159A1 (en) | 2010-06-21 | 2011-12-29 | Ono Pharmaceutical Co., Ltd. | New crystalline forms of 4,4'-[4-fluoro-7-({4-[4-(3-fluoro-2-methylphenyl)butoxy]phenyl}ethynyl)-2-methyl-1h-indole-1,3-diyl]dibutanoic acid, 4,4'-[2-methyl-7-({4-[4-(pentafluorophenyl)butoxy]phenyl}ethynyl)-1h-indole-1,3-diyl]dibutanoic acid, and 4,4'-[4-fluoro-2-methyl-7-({4-[4-(2,3,4,6-tetrafluorophenyl)butoxy]phenyl}ethynyl)-1h-indole-1,3-diyl]dibutano |
CA2803292C (en) | 2010-06-30 | 2016-06-14 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
US20130259830A1 (en) | 2010-07-12 | 2013-10-03 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators |
WO2012009137A1 (en) | 2010-07-12 | 2012-01-19 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators |
EP2637659B1 (en) | 2010-11-09 | 2016-05-18 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
SG193902A1 (en) | 2011-04-14 | 2013-11-29 | Actelion Pharmaceuticals Ltd | 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators |
JP6054600B2 (ja) * | 2011-08-11 | 2016-12-27 | 富士通コンポーネント株式会社 | コネクタ |
JP2015500326A (ja) | 2011-12-16 | 2015-01-05 | アトピックス テラピューティクス リミテッド | 好酸球性食道炎の治療のためのcrth2拮抗薬およびプロトンポンプ阻害薬の組み合わせ |
WO2013101830A1 (en) | 2011-12-27 | 2013-07-04 | Ironwood Pharmaceuticals, Inc. | 2 - benzyl, 3 - (pyrimidin- 2 -yl) substituted pyrazoles useful as sgc stimulators |
KR102205774B1 (ko) | 2012-03-21 | 2021-01-20 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 모발 성장을 조절하는 방법 및 조성물 |
WO2014047111A1 (en) | 2012-09-18 | 2014-03-27 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
CA2885645A1 (en) | 2012-09-19 | 2014-03-27 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
EP3998260B1 (en) | 2013-03-15 | 2023-11-01 | Cyclerion Therapeutics, Inc. | Sgc stimulators |
JP2016540017A (ja) | 2013-12-11 | 2016-12-22 | アイアンウッド ファーマシューティカルズ インコーポレイテッド | sGC刺激物質 |
US20160324856A1 (en) | 2014-01-13 | 2016-11-10 | Ironwood Pharmaceuticals, Inc. | Use of sgc stimulators for the treatment of neuromuscular disorders |
SI3119779T1 (sl) | 2014-03-17 | 2018-10-30 | Idorsia Pharmaceuticals Ltd | Derivati azaindolocetne kisline in njihova uporaba kot modulatorji prostaglandinskega receptorja D2 |
MX2016011900A (es) | 2014-03-18 | 2016-12-05 | Actelion Pharmaceuticals Ltd | Derivados de acido azaindol-acetico y su uso como moduladores del receptor de prostaglandina d2. |
GB201407820D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
GB201407807D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
CA2959757A1 (en) | 2014-09-17 | 2016-03-24 | Ironwood Pharmaceuticals, Inc. | Pyrazole derivatives as sgc stimulators |
WO2016044445A2 (en) | 2014-09-17 | 2016-03-24 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
US10844064B2 (en) | 2014-09-17 | 2020-11-24 | Cyclerion Therapeutics, Inc. | sGC stimulators |
WO2016128565A1 (en) | 2015-02-13 | 2016-08-18 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus |
EP3328500B1 (en) | 2015-07-30 | 2023-04-12 | The Trustees of the University of Pennsylvania | Single nucleotide polymorphic alleles of human dp-2 gene for detection of susceptibility to hair growth inhibition by pgd2 antagonists |
PL3350179T3 (pl) | 2015-09-15 | 2021-08-02 | Idorsia Pharmaceuticals Ltd | Krystaliczne postacie |
AU2017291826B2 (en) | 2016-07-07 | 2021-10-21 | Cyclerion Therapeutics, Inc. | Phosphorus prodrugs of sGC stimulators |
BR112019000293A2 (pt) | 2016-07-07 | 2019-04-16 | Ironwood Pharmaceuticals, Inc. | formas sólidas de um estimulador de sgc |
CA3167217A1 (en) | 2020-01-13 | 2021-07-22 | Durect Corporation | Sustained release drug delivery systems with reduced impurities and related methods |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US741360A (en) * | 1899-11-13 | 1903-10-13 | William M Moseley | Toy. |
BE790679A (fr) | 1971-11-03 | 1973-04-27 | Ici Ltd | Derives de l'indole |
JPH0615542B2 (ja) | 1986-07-22 | 1994-03-02 | 吉富製薬株式会社 | ピラゾロピリジン化合物 |
NZ222878A (en) * | 1986-12-17 | 1991-02-26 | Merck Frosst Canada Inc | 3-hetero-substituted-n-benzyl-indole derivatives, and pharmaceutical compositions |
US5095031A (en) | 1990-08-20 | 1992-03-10 | Abbott Laboratories | Indole derivatives which inhibit leukotriene biosynthesis |
WO1993005020A1 (en) | 1991-09-06 | 1993-03-18 | Merck & Co., Inc. | Indoles as inhibitors of hiv reverse transcriptase |
CA2079374C (en) * | 1991-09-30 | 2003-08-05 | Merck Frosst Canada Incorporated | (bicyclic-azaarylmethoxy)indoles as inhibitors of leukotriene biosynthesis |
FR2692574B1 (fr) | 1992-06-23 | 1995-06-23 | Sanofi Elf | Derives hydroxy-4 benzenethio, leur preparation ainsi que leur utilisation pour la preparation de derives aminoalkoxybenzenesulfonyles. |
HUT74614A (en) | 1993-02-24 | 1997-01-28 | Merck & Co Inc | Nindol derivates suitable for treatment of infection by hiv and pharmaceutical compositions containing them |
US5486525A (en) | 1993-12-16 | 1996-01-23 | Abbott Laboratories | Platelet activating factor antagonists: imidazopyridine indoles |
US5482960A (en) * | 1994-11-14 | 1996-01-09 | Warner-Lambert Company | Nonpeptide endothelin antagonists |
US5567711A (en) | 1995-04-19 | 1996-10-22 | Abbott Laboratories | Indole-3-carbonyl and indole-3-sulfonyl derivatives as platelet activating factor antagonists |
TW472045B (en) * | 1996-09-25 | 2002-01-11 | Astra Ab | Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation |
AR017256A1 (es) | 1997-08-21 | 2001-09-05 | American Home Prod | Compuestos de indol sustituidos, metodo para la sintesis en fase solida de los mismos, conjuntos de combinacion para ser empleados en dicho metodo, uso delos compuestos para preparar un medicamento y composiciones farmaceuticas que los comprenden |
ATE239013T1 (de) | 1997-12-19 | 2003-05-15 | Lilly Co Eli | Hypoglykamische imidazoline derivate |
US6916841B2 (en) | 1998-02-25 | 2005-07-12 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
AU5886500A (en) | 1999-06-23 | 2001-01-09 | Sepracor, Inc. | Indolyl-benzimidazole antibacterials, and methods of use thereof |
WO2001032621A1 (fr) | 1999-10-29 | 2001-05-10 | Wakunaga Pharmaceutical Co., Ltd. | Nouveaux derives d'indole, et medicaments contenant lesdits derives comme principe actif |
AP1917A (en) | 1999-12-24 | 2008-11-12 | Aventis Pharma Ltd | Azaindoles |
CA2406979A1 (en) | 2000-05-31 | 2001-12-06 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
IL153688A0 (en) * | 2000-06-28 | 2003-07-06 | Teva Pharma | Carvedilol |
US6878522B2 (en) | 2000-07-07 | 2005-04-12 | Baiyong Li | Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2 |
BR0212925A (pt) * | 2001-09-27 | 2004-10-13 | Hoffmann La Roche | Derivados de idol como inibidores de cox ii |
TWI317634B (en) | 2001-12-13 | 2009-12-01 | Nat Health Research Institutes | Aroyl indoles compounds |
ES2271551T3 (es) | 2002-02-01 | 2007-04-16 | F. Hoffman-La Roche Ag | Indoles sustituidos com agonistas alfa-1. |
SE0200356D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
SE0200411D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
WO2003097598A1 (fr) | 2002-05-16 | 2003-11-27 | Shionogi & Co., Ltd. | Composé comprenant un antagonisme du récepteur de pdg2 |
SE0201635D0 (sv) | 2002-05-30 | 2002-05-30 | Astrazeneca Ab | Novel compounds |
TW200307542A (en) | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
SE0202241D0 (sv) | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
SE0202463D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel compounds |
SE0301569D0 (sv) | 2003-05-27 | 2003-05-27 | Astrazeneca Ab | Novel compounds |
SE0302232D0 (sv) | 2003-08-18 | 2003-08-18 | Astrazeneca Ab | Novel Compounds |
CA2542716A1 (en) | 2003-10-14 | 2005-05-06 | Oxagen Limited | Compounds having crth2 antagonist activity |
SE0303180D0 (sv) | 2003-11-26 | 2003-11-26 | Astrazeneca Ab | Novel compounds |
GB0500604D0 (en) | 2005-01-13 | 2005-02-16 | Astrazeneca Ab | Novel process |
GB2422831A (en) | 2005-02-04 | 2006-08-09 | Oxagen Ltd | Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor |
JP2009538289A (ja) * | 2006-05-26 | 2009-11-05 | アストラゼネカ・アクチエボラーグ | ビアリールまたはヘテロアリール置換インドール |
RU2008152763A (ru) | 2006-06-08 | 2010-07-20 | Ньюроки А/С (Dk) | Применение агонистов каннабиноидного рецептора в качестве индуцирующих гипотермию лекарственных средств для лечения ишемии |
EP2040688B1 (en) | 2006-06-28 | 2014-04-02 | Sanofi | New cxcr2 inhibitors |
-
2002
- 2002-07-17 SE SE0202241A patent/SE0202241D0/xx unknown
- 2002-12-13 SE SE0203713A patent/SE0203713D0/xx unknown
-
2003
- 2003-07-07 TW TW092118486A patent/TW200404778A/zh unknown
- 2003-07-15 CA CA002492445A patent/CA2492445A1/en not_active Abandoned
- 2003-07-15 ES ES03764279T patent/ES2335491T3/es not_active Expired - Lifetime
- 2003-07-15 DE DE60330372T patent/DE60330372D1/de not_active Expired - Lifetime
- 2003-07-15 PT PT03764279T patent/PT1551802E/pt unknown
- 2003-07-15 BR BR0312729-0A patent/BR0312729A/pt not_active IP Right Cessation
- 2003-07-15 NZ NZ537606A patent/NZ537606A/en unknown
- 2003-07-15 US US10/521,325 patent/US7723373B2/en not_active Expired - Fee Related
- 2003-07-15 MX MXPA05000646A patent/MXPA05000646A/es unknown
- 2003-07-15 CN CNB038199718A patent/CN1279023C/zh not_active Expired - Fee Related
- 2003-07-15 WO PCT/SE2003/001216 patent/WO2004007451A1/en active Application Filing
- 2003-07-15 JP JP2004521364A patent/JP4791729B2/ja not_active Expired - Fee Related
- 2003-07-15 DK DK03764279.0T patent/DK1551802T3/da active
- 2003-07-15 AT AT03764279T patent/ATE450506T1/de active
- 2003-07-15 AU AU2003251260A patent/AU2003251260B2/en not_active Expired - Fee Related
- 2003-07-15 EP EP03764279A patent/EP1551802B1/en not_active Expired - Lifetime
- 2003-07-15 SI SI200331737T patent/SI1551802T1/sl unknown
- 2003-07-17 AR AR20030102585A patent/AR040498A1/es not_active Application Discontinuation
-
2005
- 2005-01-03 IL IL16612105A patent/IL166121A0/xx unknown
- 2005-01-07 ZA ZA200500170A patent/ZA200500170B/xx unknown
- 2005-02-16 NO NO20050828A patent/NO20050828L/no not_active Application Discontinuation
-
2010
- 2010-01-28 CY CY20101100086T patent/CY1109760T1/el unknown
- 2010-04-12 US US12/758,348 patent/US20100197756A1/en not_active Abandoned
- 2010-07-23 JP JP2010166138A patent/JP2010280680A/ja not_active Withdrawn
-
2011
- 2011-03-01 JP JP2011043693A patent/JP2011116770A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
ES2335491T3 (es) | 2010-03-29 |
CN1279023C (zh) | 2006-10-11 |
NO20050828L (no) | 2005-04-05 |
JP4791729B2 (ja) | 2011-10-12 |
IL166121A0 (en) | 2006-01-15 |
DK1551802T3 (da) | 2010-03-15 |
PT1551802E (pt) | 2010-02-02 |
AR040498A1 (es) | 2005-04-06 |
WO2004007451A1 (en) | 2004-01-22 |
US20100197756A1 (en) | 2010-08-05 |
SI1551802T1 (sl) | 2010-03-31 |
JP2005537265A (ja) | 2005-12-08 |
MXPA05000646A (es) | 2005-06-02 |
NZ537606A (en) | 2006-08-31 |
JP2010280680A (ja) | 2010-12-16 |
JP2011116770A (ja) | 2011-06-16 |
ATE450506T1 (de) | 2009-12-15 |
CN1678579A (zh) | 2005-10-05 |
DE60330372D1 (de) | 2010-01-14 |
AU2003251260B2 (en) | 2007-04-26 |
ZA200500170B (en) | 2006-02-22 |
EP1551802A1 (en) | 2005-07-13 |
US7723373B2 (en) | 2010-05-25 |
EP1551802B1 (en) | 2009-12-02 |
CY1109760T1 (el) | 2014-09-10 |
BR0312729A (pt) | 2005-05-10 |
US20060111426A1 (en) | 2006-05-25 |
SE0203713D0 (sv) | 2002-12-13 |
AU2003251260A1 (en) | 2004-02-02 |
CA2492445A1 (en) | 2004-01-22 |
TW200404778A (en) | 2004-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SE0202241D0 (sv) | Novel Compounds | |
TW200407305A (en) | Novel compounds | |
TW200510301A (en) | Novel compounds | |
TW200510303A (en) | Novel compounds | |
SE0303180D0 (sv) | Novel compounds | |
SE0301010D0 (sv) | Novel compounds | |
SE0301009D0 (sv) | Novel compounds | |
TW200612892A (en) | Novel compounds | |
MX2007011847A (es) | Derivados de pirimidindiona como antagonistas del receptor de procineticina 2. | |
EA200900828A1 (ru) | Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1 | |
TW200732296A (en) | Novel compounds | |
DE60229530D1 (de) | Substituierte piperazine als modulatoren des melanocortinrezeptors | |
MY153719A (en) | Prokineticin 1 receptor antagonists | |
MX2007011695A (es) | Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos. | |
MX2007011698A (es) | Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos. | |
DE602006014305D1 (de) | Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors | |
ATE449776T1 (de) | Pyrroloä2,3-cüpyridinderivate | |
TW200745039A (en) | Isotopically substituted pantoprazole | |
MY141528A (en) | Anilinopyrazole derivatives useful for the treatment of diabetes | |
TNSN06012A1 (en) | Emulsifying systems containing azetidine derivatives | |
UA106200C2 (uk) | Заміщені похідні оксіндолу та їхнє застосування для лікування захворювань, залежних від вазопресину | |
DE60316128D1 (de) | N-sulfonylurea-apoptosis-förderer | |
ATE486078T1 (de) | 5,6-disubstituierte oxadiazolopyrazine und thiadiazolopyrazine als liganden des cxc- chemokinrezeptors | |
EA200602081A1 (ru) | Пиридиновые производные алкилоксиндолов в качестве агентов, активных в отношении рецептора 5-нт7 | |
UA84701C2 (ru) | Замещенные индолы, способ их получения, их использования |